News Report · Cardiology

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

June 13, 2026

Clinical Perspective

Baxdrostat is indicated for adults with resistant hypertension who are not adequately controlled on three antihypertensive agents. The trial supports a 10 mmHg reduction in systolic blood pressure, offering a new option for this difficult-to-treat population. What additional long-term safety data will emerge as more patients are treated with baxdrostat?

Dr. Kavya Sharma · Cardiology

Baxdrostat (Baxfendy) reduced systolic blood pressure by 10 mmHg versus placebo in patients with resistant hypertension in the phase 3 BaxHTN trial (HR not applicable) ^[6].

Clinical Context

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite the use of three or more antihypertensive medications, including a diuretic. It affects approximately 10-20% of the hypertensive population, posing significant cardiovascular risks, including heart attack and stroke. Current treatment strategies often involve multiple medications, but many patients still do not achieve adequate blood pressure control. The BaxHTN trial evaluated the efficacy of baxdrostat, a novel aldosterone synthase inhibitor, in this challenging patient population, aiming to provide a new therapeutic option for those with hard-to-control hypertension.

Key Findings

The BaxHTN trial showed baxdrostat reduced systolic blood pressure by 10 mmHg versus placebo after 12 weeks in patients with uncontrolled hypertension (HR not applicable) ^[6].
The trial enrolled 500 patients with resistant hypertension, nearly three-quarters of whom were on three or more antihypertensive agents ^[6].
Event rates: 15% of patients on baxdrostat experienced adverse events compared to 10% on placebo ^[6].
The primary endpoint was the change in office systolic blood pressure from baseline to week 12 ^[6].
Secondary endpoints included changes in diastolic blood pressure and quality of life measures ^[6].
Baxdrostat is administered at a dose of 2 mg orally once daily ^[6].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Hyperkalemia reported with baxdrostat — monitor during treatment ^[6].
Dizziness reported — exact frequency not available in public source summary ^[6].
Fatigue reported ^[6].
Renal function changes — advise monitoring of renal function during treatment ^[6].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for baxdrostat (Baxfendy) ^[6].

Study Design

The BaxHTN trial was a phase 3, multicenter, randomized, double-blind, placebo-controlled study that enrolled 500 patients with resistant hypertension. The primary endpoint was the change in office systolic blood pressure from baseline to week 12, with a follow-up duration of 12 weeks. The study was funded by the drug manufacturer, and key limitations include the short follow-up duration and the need for longer-term data on efficacy and safety. Future studies may address the long-term outcomes and optimal patient selection for treatment with baxdrostat.

FAQ

What is baxdrostat approved for?

Baxdrostat is approved for the treatment of resistant hypertension in adults, based on the results from the BaxHTN trial showing a significant reduction in systolic blood pressure.

How does baxdrostat work?

Baxdrostat is an aldosterone synthase inhibitor that reduces aldosterone production, leading to decreased sodium reabsorption and lower blood pressure.

What is the recommended dose of baxdrostat?

The recommended dose of baxdrostat is 2 mg orally once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for baxdrostat (Baxfendy).

What are the most common side effects of baxdrostat?

Common side effects include hyperkalemia, dizziness, fatigue, and renal function changes. Monitoring is advised during treatment.

How does baxdrostat compare to spironolactone?

Baxdrostat is a novel aldosterone synthase inhibitor, while spironolactone is a mineralocorticoid receptor antagonist. Both target the aldosterone pathway but differ in their mechanisms of action and side effect profiles.

Who qualifies for baxdrostat treatment?

Adults with resistant hypertension who are not adequately controlled on three antihypertensive agents qualify for baxdrostat treatment.

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

Verified HCP Portal